MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable tissue in patients with deep partial- and full-thickness thermal burns. It is ...

In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their TD Cowen representative to schedule a meeting.

Learn more about whether PTC Therapeutics, Inc. or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.